 Press ReleasesAugust 2007 Photopharmica Appoints Two Non-Executive Directors Photopharmica Limited ("Photopharmica" or "the Company"), a University of Leeds spin-out company which is developing pharmaceutical products using photodynamic therapy (PDT), is delighted to announce the appointment of Dr Sam Williams and Dr Ian Wilding as Non-Executive Directors with immediate effect. Dr Williams is Chief Executive Officer of the drug development company, Modern Biosciences plc ("MBS"). He joined MBS in April from Lehman Brothers where he was Industry Group Leader for European Pharmaceuticals and Chemicals. Sam was ranked the number one European Biotechnology equity analyst by Institutional Investor magazine in 2004, 2005 and 2006 and by Thomson Extel in 2004 and 2005. Sam has over ten years' experience in the financial services industry as well as expert life sciences knowledge, particularly in molecular biology. Dr Wilding, who is MBS' Chief Scientific Officer, was one of the founders of Pharmaceutical Profiles, a successful spin-out company from Nottingham University. Prior to an MBO in January 2005, Ian had served as the Chief Executive and Chairman of Pharmaceutical Profiles, specialising in early phase clinical trials for over 15 years. Dr Wilding has published over 250 research papers/abstracts in the area of drug absorption /delivery and in 2005 received the CRS "Career Achievement Award in Oral Drug Delivery". In 1997 he served as an expert scientist for the FDA and is recognised globally as an innovator in early drug development. > menu |
